Dr. Frank Hensel

Principal / Authorized signatory

Dr. Frank Hensel

Principal / Authorized signatory

Dr Frank Hensel holds a PH.D. in biology and has a longstanding experience as Entrepreneur in a Start-Up developing human monoclonal antibodies for cancer treatment. Since being part of HTGF in 2015 Frank built a solid portfolio of start-ups with a focus on drug development companies. Out of this portfolio 3 companies already entered the clinical stage and one company, Amal therapeutics, was successfully exited to Boehringer Ingelheim with a deal volume of up to 425Mio. €

Contact

Telefon:
+49 – (0)228 – 82300 – 142

Portfolio

Posts & mentions

Press
14. October 2021

BASF Venture Capital and Amathaon Capital Acquire Minority Stake in Bioinformatics Company Computomics

Computomics AI recommends crosses adapted to future climatic conditionsPlant breeders can significantly accelerate market launch of new varietiesInvestment promotes innovative solutions for more sustainable agriculture Tübingen, Munich and Ludwigshafen, October 14, 2021 - BASF Venture Capital GmbH (BVC), the corporate venture company of BASF Group, and Amathaon Capital, a venture capital company specializing in AgTech, are investing in the Tübingen-based bioinformatics company Compu
 
Press
15. June 2021

Alentis Therapeutics Raises USD 67 Million in Series B Financing

Funding to Advance Pipeline of Anti-fibrotic Molecules into the Clinic Basel, Switzerland and Strasbourg, France, 15 June 2021 - Alentis Therapeutics, the Swiss biotech developing breakthrough treatments for fibrotic diseases, today announced that it has raised USD67 (CHF60) million in a Series B financing round. The funding will be used primarily for proof-of-concept clinical trials of Alentis’ first in class, Claudin-1 targeting, anti-fibrotic molecules in advanced liver and